BEVERLY, MA--(Marketwire - December 10, 2012) - Cellceutix Corporation (OTCBB: CTIX) (the Company), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, today announced that it has entered into a common stock purchase agreement (the Purchase Agreement) with Aspire Capi